Last week, Pfizer, Inc. (“Pfizer”) filed two petitions for inter partes review (“IPR”) of two patents related to Genentech and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
IPR
-
-
On October 3, 2017, Pfizer, Inc. (“Pfizer”) filed a petition for inter partes review (“IPR”) against U.S. Patent No. 7,846,441...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Sandoz, Inc. (“Sandoz”) entered into the battlefield over patents related to AbbVie’s Humira® (adalimumab). On July 20, 2017,...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On June 30, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 8,591,897...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Partner Nikki Gifford gave a presentation entitled “Intellectual Property – Recent Developments and Implications,” at the World...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The battle over the proper forum for patent infringement litigation regarding Dupixent® (Dupilumab) appears to have been resolved. Last...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Over the last two weeks, Pfizer, Inc. (“Pfizer”) has filed petitions for inter partes review (“IPR”) of three additional patents...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]